Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.64), $0.11 worse than the analyst estimate of ($1.53).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Green Dot and CommerceOne shareholders approve acquisition deal
• Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors